Emyria & UWA Partner to License Novel Serotonin Therapies
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Emyria Ltd has announced an exclusive licence agreement with the University of Western Australia, granting worldwide rights to a portfolio of serotonin-releasing agents aimed at treating mental health and neurological conditions. This partnership is supported by a government grant and aims to enhance treatment outcomes while minimizing side effects associated with existing therapies.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Emyria
- September 2024 Quarterly Activities Report and Appendix 4C
- Emyria Gains Ethics Endorsement for Psilocybin Program
- Emyria Shares Interim Success in PTSD Treatment Program
- Appendix 4E & Annual Report for the Year Ended 30 June 2024
- June 2024 Quarterly Activities Report and Appendix 4C
Later from Emyria
- Response to ASX Price Query
- Emyria Secures $2.525M in Strongly Supported Placement
- Leadership Updates
- December 2024 Quarterly Activities Report and Appendix 4C
- Emyria Reports Promising 3-Month PTSD Treatment Results
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria